查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370907

循环肿瘤细胞市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按技术、按应用、产品、样本、地区、竞争细分

Circulating Tumor Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology, By Application, By Product, By Specimen, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球循环肿瘤细胞市场在2022年达到98.1亿美元的估值，预计在预测期内将大幅成长，到2028年复合年增长率（CAGR）为9.20%，预计2028年将达到165.4亿美元。循环肿瘤细胞（CTC）市场围绕着识别和分析从原发肿瘤分离并进入血液的癌细胞。 CTC 具有重要的诊断和预后价值，可深入了解疾病进展、治疗效果以及向身体其他部位的潜在扩散。该市场包含一系列创新技术和方法，旨在从血液样本中分离、量化和表征这些稀有细胞。透过实现癌症和治疗反应的非侵入性监测，CTC 市场在个人化医疗和治疗决策中发挥着至关重要的作用。随着该领域的进步，微流控、成像技术和分子分析技术的突破有助于提高 CTC 检测的敏感度和特异性。

主要市场驱动因素

转向个人化医疗

市场概况
预测期 2024-2028
2022 年市场规模 98.1亿美元
2028 年市场规模 165.4亿美元
2023-2028 年复合年增长率 9.20%
成长最快的细分市场 研究
最大的市场 北美洲

个人化医疗的趋势强烈推动了对循环肿瘤细胞（CTC）市场的需求。个人化医疗根据患者独特的遗传和分子特征为个别患者量身定制治疗方案。 CTC 测试与这种方法无缝结合，为临床医生和患者提供了备受追捧的工具。与遵循标准化方法的传统癌症治疗不同，CTC 测试可以即时了解疾病状态和治疗反应。当癌细胞进入血液时，CTC 提供肿瘤遗传和分子特征的动态表示。这使得肿瘤学家能够监测治疗效果、检测抗药性并对治疗计划做出明智的调整。

CTC 检测的非侵入性

循环肿瘤细胞 (CTC) 检测的非侵入性是 CTC 市场需求不断增长的主要动力。与传统的侵入性肿瘤活检不同，CTC 检测提供了一种微创方式来收集有关患者癌症状态的关键资讯。这对癌症诊断和治疗监测具有变革性影响，吸引了医疗保健专业人员和患者的兴趣。传统的活检可能会导致不适、併发症和恢復时间缩短。相较之下，CTC 检测只需进行简单的抽血，即可减少患者的焦虑并消除与侵入性操作相关的风险。

CTC 检测也解决了定期癌症监测的需求。频繁监测对于评估治疗反应和疾病进展至关重要，但由于侵入性，重复活检是不切实际的。 CTC 测试可以透过血液样本进行定期监测，无需侵入性操作即可提供即时见解。这与以患者为中心的护理一致，满足对破坏性最小的诊断的偏好。

CTC 检测的非侵入性方法在难以取得组织样本的挑战性情况下非常有价值。此外，CTC 测试透过提供对肿瘤异质性的更广泛了解来补充传统活检。这方面有助于扩大癌症筛检和早期检测工作，与在最早、最可治疗的阶段识别癌症的目标保持一致。

癌症盛行率上升

癌症盛行率的增加是循环肿瘤细胞（CTC）市场需求的关键驱动力。由于癌症仍然是全球健康挑战，因此对准确诊断工具的需求至关重要。 CTC 测试透过提供对疾病进展和治疗反应的见解来满足这一需求。世界卫生组织预计，由于人口老化、生活方式的改变和环境因素，癌症发生率将显着上升。癌症盛行率的不断上升推动了对早期检测、治疗监测和个人化治疗的有效方法的需求。

CTC 检测透过在肿瘤在成像扫描中可见之前或在症状出现之前识别血液中的癌细胞来实现早期检测。早期发现可以早期介入、改善结果并降低发病率。 CTC 测试还透过提供对肿瘤遗传学和分子特征的见解来支持治疗监测和个人化方法。此外，CTC 测试加速了临床试验和药物开发，并加快了药物疗效和安全性的评估。

癌症盛行率的上升凸显了个人化治疗的重要性。 CTC 测试在这方面发挥关键作用，为客製化疗法提供对遗传和分子特征的见解。随着癌症发生率的增加，对 CTC 检测的需求持续增长，使其成为应对癌症挑战的重要工具。

主要市场挑战

检测灵敏度和特异性

检测灵敏度和特异性对循环肿瘤细胞 (CTC) 市场提出了重大挑战，影响了 CTC 检测的准确性和可靠性。 CTC 是血液中少量存在的稀有细胞，因此检测技术要求很高。平衡灵敏度（检测低水平的 CTC）和特异性（准确地区分 CTC 与其他细胞）对于有效的 CTC 检测至关重要。检测不充分可能会导致假阴性，从而延迟诊断和治疗决策。要实现高灵敏度需要更灵敏的技术来检测数十亿正常细胞中的单一 CTC。确保特异性对于避免误报同样重要，误报可能导致不必要的介入和患者焦虑。

实现敏感性和特异性需要持续创新、跨学科合作和严格的验证研究。整合先进的成像、微流体和分子分析可提高 CTC 检测精度。标准化方案和品质控制确保实验室之间的一致性。

CTC 的异质性

循环肿瘤细胞 (CTC) 的异质性为 CTC 市场带来了重大挑战。 CTC 表现出多种遗传和表型特征，这些特征在肿瘤内部和肿瘤之间各不相同。应对这项挑战需要捕获 CTC 亚群的技术。整合先进的分子分析有助于了解 CTC 多样性。纵向分析可以追踪随时间的变化。

克服 CTC 异质性需要跨学科合作和技术进步。微流控、成像和高通量定序可捕捉不同的 CTC。标准化协议确保一致性。

成本考虑

成本考量会影响 CTC 测试的采用和可近性。先进技术、专业培训和设备维护都会增加成本。患者对负担能力和保险范围的担忧会影响决策。解决成本挑战涉及技术开发、合作和规模经济。创新和合作可以带来具有成本效益的解决方案。

主要市场趋势

下一代定序 (NGS) 的集成

次世代定序 (NGS) 整合改变了循环肿瘤细胞 (CTC) 市场。 NGS 分析 CTC 遗传学，揭示突变、变异和基因表现。这一趋势增强了对肿瘤的了解，指导治疗决策并推进个人化护理。 NGS 捕获遗传异质性，识别标靶治疗的突变。这一趋势加速了研究转化。

用于早期检测的液体活检

液体活检，包括 CTC 检测，是早期癌症检测的趋势。 CTC 检测可在肿瘤可见或出现症状之前检测血液中的癌细胞。这种非侵入性方法可以及时进行干预，特别是对于侵袭性癌症。液体活检与标靶治疗一致，有助于治疗决策。

细分市场洞察

技术： Ctc 检测和富集技术占主导地位。 「CTC 分析」和「CTC 直接检测」由于成像和分子分析的进步而受到关注。

应用：临床/液体活检领先，彻底改变癌症护理。早期检测和治疗监测推动了采用。

区域洞察

北美由于医疗基础设施、研究和有利的法规而占据主导地位。领先机构和产业合作巩固了其领导地位。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球循环肿瘤细胞市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术分类（CTC 检测与富集、CTC 直接检测、CTC 分析）
    • 按应用（临床/液体活检、研究）
    • 副产品（设备或系统、试剂盒及试剂、采血管）
    • 依样本（骨髓、血液、其他体液）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图

第 6 章：北美循环肿瘤细胞市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按应用
    • 按产品分类
    • 按样本
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲循环肿瘤细胞市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按应用
    • 按产品分类
    • 按样本
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区循环肿瘤细胞市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按应用
    • 按产品分类
    • 按样本
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲循环肿瘤细胞市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按应用
    • 按产品分类
    • 按样本
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲循环肿瘤细胞市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按应用
    • 按产品分类
    • 按样本
    • 按国家/地区
  • MEA：国家分析
    • 南非循环肿瘤细胞
    • 沙乌地阿拉伯循环肿瘤细胞
    • 阿联酋循环肿瘤细胞

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Greiner Bio One International GmbH
    • LineaRx, Inc. (Vitatex, Inc.)
    • Bio-Techne Corporation
    • Biolidics Limited
    • Fluxion Biosciences, Inc.
    • Creatv MicroTech, Inc.
    • Canopus Bioscience Ltd.
    • AVIVA Biosciences Corp
    • Miltenyi Biotec Inc
    • QIAGEN NV

第 16 章：策略建议

简介目录
Product Code: 15903

Global Circulating Tumor Cells Market achieved a valuation of USD 9.81 Billion in 2022 and is expected to experience substantial growth during the forecast period, with a Compound Annual Growth Rate (CAGR) of 9.20% until 2028 and expected to reach USD 16.54 Billion in 2028. The Circulating Tumor Cells (CTC) Market revolves around identifying and analyzing cancer cells that detach from primary tumors and enter the bloodstream. CTCs hold significant diagnostic and prognostic value, offering insights into disease progression, treatment effectiveness, and potential spread to other parts of the body. This market encompasses a range of innovative technologies and methods designed to isolate, quantify, and characterize these rare cells from blood samples. By enabling non-invasive monitoring of cancer and treatment response, the CTC market plays a crucial role in personalized medicine and treatment decision-making. As the field advances, breakthroughs in microfluidics, imaging technologies, and molecular analysis techniques contribute to enhancing the sensitivity and specificity of CTC detection.

Key Market Drivers

Shift towards Personalized Medicine

Market Overview
Forecast Period2024-2028
Market Size 2022USD 9.81 Billion
Market Size 2028USD 16.54 Billion
CAGR 2023-20289.20%
Fastest Growing SegmentResearch
Largest MarketNorth America

The trend towards personalized medicine strongly drives the demand for the Circulating Tumor Cells (CTC) Market. Personalized medicine tailors medical treatments to individual patients based on their unique genetic and molecular characteristics. CTC testing aligns seamlessly with this approach, offering a highly sought-after tool for clinicians and patients. Unlike traditional cancer treatments that follow a standardized approach, CTC testing provides real-time insights into disease status and treatment response. As cancer cells enter the bloodstream, CTCs offer a dynamic representation of the tumor's genetic and molecular profile. This empowers oncologists to monitor treatment effectiveness, detect drug resistance, and make informed adjustments to the treatment plan.

Personalized medicine aims to enhance treatment outcomes while minimizing adverse effects. CTC testing guides clinicians in identifying targeted therapies that are more likely to be effective. Analyzing the genetic mutations and markers of CTCs allows healthcare providers to recommend treatments matched to the patient's tumor profile, improving response rates and reducing side effects. Additionally, CTC testing aids in predicting a patient's prognosis by studying changes in CTC genetics over time, providing insights into tumor behavior and aiding treatment decisions.

The demand for CTC testing aligns with advancements in technology, including microfluidic platforms, imaging, and molecular analysis. These innovations enhance the precision of CTC detection, supporting personalized cancer care. As personalized medicine gains momentum, CTC testing becomes increasingly valuable, providing insights into tumor behavior, treatment response, and prognosis.

Non-Invasive Nature of CTC Testing

The non-invasive nature of Circulating Tumor Cells (CTC) testing is a major driver behind the growing demand for the CTC Market. Unlike traditional tumor biopsies that are invasive, CTC testing offers a minimally invasive way to gather critical information about a patient's cancer status. This has transformative implications for cancer diagnosis and treatment monitoring, attracting interest from healthcare professionals and patients. Traditional biopsies can cause discomfort, complications, and recovery time. In contrast, CTC testing involves a simple blood draw, reducing patient anxiety and eliminating risks associated with invasive procedures.

CTC testing also addresses a need for regular cancer monitoring. Frequent monitoring is essential for assessing treatment response and disease progression, but repeated biopsies are impractical due to invasiveness. CTC testing allows regular monitoring through blood samples, offering real-time insights without invasive procedures. This aligns with patient-centric care, meeting the preference for minimally disruptive diagnostics.

The non-invasive approach of CTC testing is valuable in challenging cases where tissue samples are hard to obtain. Additionally, CTC testing complements traditional biopsies by providing a broader understanding of tumor heterogeneity. This aspect contributes to expanding cancer screening and early detection efforts, aligning with the goal of identifying cancer at its earliest, most treatable stage.

Rising Prevalence of Cancer

The increasing prevalence of cancer is a key driver of demand in the Circulating Tumor Cells (CTC) Market. As cancer remains a global health challenge, the need for accurate diagnostic tools is critical. CTC testing addresses this need by offering insights into disease progression and treatment response. The World Health Organization projects a significant rise in cancer incidence due to aging populations, lifestyle changes, and environmental factors. This growing cancer prevalence drives demand for effective methods of early detection, treatment monitoring, and personalized therapies.

CTC testing addresses early detection by identifying cancer cells in the bloodstream before tumors become visible on imaging scans or before symptoms appear. Early detection leads to earlier interventions, improved outcomes, and reduced morbidity. CTC testing also supports treatment monitoring and personalized approaches by offering insights into tumor genetics and molecular characteristics. Additionally, CTC testing accelerates clinical trials and drug development, expediting the assessment of drug efficacy and safety.

The rising cancer prevalence underscores the importance of personalized treatment. CTC testing plays a pivotal role in this context, offering insights into genetic and molecular characteristics for tailored therapies. As cancer rates increase, the demand for CTC testing continues to grow, positioning it as a vital tool in addressing the challenge of cancer.

Key Market Challenges

Detection Sensitivity and Specificity

Detection sensitivity and specificity present significant challenges in the Circulating Tumor Cells (CTC) Market, affecting the accuracy and reliability of CTC testing. CTCs are rare cells present in small quantities in the bloodstream, making their detection technically demanding. Balancing sensitivity (detecting low levels of CTCs) and specificity (accurately distinguishing CTCs from other cells) is crucial for effective CTC testing. Insufficient detection can lead to false negatives, delaying diagnosis and treatment decisions. Achieving high sensitivity requires more sensitive technologies to detect even a single CTC among billions of normal cells. Ensuring specificity is equally important to avoid false positives, which can lead to unnecessary interventions and patient anxiety.

Achieving both sensitivity and specificity requires continuous innovation, interdisciplinary collaboration, and rigorous validation studies. Integrating advanced imaging, microfluidics, and molecular analysis enhances CTC detection precision. Standardized protocols and quality control ensure consistency across laboratories.

Heterogeneity of CTCs

The heterogeneity of Circulating Tumor Cells (CTCs) poses a significant challenge in the CTC Market. CTCs exhibit diverse genetic and phenotypic characteristics that vary within and among tumors. Addressing this challenge requires technologies capturing CTC subpopulations. Integrating advanced molecular analysis helps understand CTC diversity. Longitudinal analysis enables tracking changes over time.

Overcoming CTC heterogeneity requires interdisciplinary collaboration and technology advancements. Microfluidics, imaging, and high-throughput sequencing capture diverse CTCs. Standardized protocols ensure consistency.

Cost Considerations

Cost considerations impact the adoption and accessibility of CTC testing. Advanced technologies, specialized training, and equipment maintenance contribute to costs. Patient concerns about affordability and insurance coverage impact decisions. Addressing cost challenges involves technology development, collaborations, and economies of scale. Innovations and collaborations can lead to cost-effective solutions.

Key Market Trends

Integration of Next-Generation Sequencing (NGS)

Next-Generation Sequencing (NGS) integration transforms the Circulating Tumor Cells (CTC) Market. NGS analyzes CTC genetics, uncovering mutations, variations, and gene expression. This trend enhances tumor understanding, guiding treatment decisions and advancing personalized care. NGS captures genetic heterogeneity, identifying mutations for targeted therapies. This trend accelerates research translation.

Liquid Biopsies for Early Detection

Liquid biopsies, including CTC testing, trend towards early cancer detection. CTC testing detects cancer cells in blood before tumors are visible or symptomatic. This non -invasive approach enables timely interventions, especially for aggressive cancers. Liquid biopsies align with targeted therapies, aiding treatment decisions.

Segmental Insights

Technology: Ctc Detection & Enrichment technology dominates. "CTC Analysis" and "CTC Direct Detection" gain traction due to imaging and molecular analysis advancements.

Application: Clinical/Liquid Biopsy leads, revolutionizing cancer care. Early detection and treatment monitoring drive adoption.

Regional Insights

North America dominates due to healthcare infrastructure, research, and favorable regulations. Leading institutions and industry collaborations solidify its leadership.

Key Market Players

  • Greiner Bio One International GmbH
  • LineaRx, Inc. (Vitatex, Inc.)
  • Bio-Techne Corporation
  • Biolidics Limited
  • Fluxion Biosciences, Inc.
  • Creatv MicroTech, Inc.
  • Canopus Bioscience Ltd.
  • AVIVA Biosciences Corp
  • Miltenyi Biotec Inc
  • QIAGEN NV

Report Scope:

In this report, the Global Circulating Tumor Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Circulating Tumor Cells Market, By Technology:

  • CTC Detection & Enrichment
  • CTC Direct Detection
  • CTC analysis

Circulating Tumor Cells Market, By Application:

  • Clinical/liquid biopsy
  • Research

Circulating Tumor Cells Market, By Product:

  • Devices or Systems
  • Kits & Reagents
  • Blood Collection Tubes

Circulating Tumor Cells Market, By Specimen:

  • Bone Marrow
  • Blood,
  • Other Body Fluids

Circulating Tumor Cells Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Circulating Tumor Cells Market.

Available Customizations:

  • Global Circulating Tumor Cells Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Circulating Tumor Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (CTC Detection & Enrichment, CTC Direct Detection, CTC analysis)
      • 5.2.1.1. By CTC Detection & Enrichment (Immunocapture/label-based, Size-based separation/label-free, Density-based separation, Combined methods)
      • 5.2.1.2. By CTC Direct Detection (Microscopy, SERS, Others)
    • 5.2.2. By Application (Clinical/liquid biopsy, Research)
      • 5.2.2.1. By Clinical/liquid biopsy (Risk assessment, Screening and Monitoring)
      • 5.2.2.2. By Research (Cancer stem cell & tumorigenesis research, Drug/therapy development)
    • 5.2.3. By Product (Devices or Systems, Kits & Reagents, Blood Collection Tubes)
    • 5.2.4. By Specimen (Bone Marrow, Blood, Other Body Fluids)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Circulating Tumor Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By Product
    • 6.2.4. By Specimen
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Circulating Tumor Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Product
        • 6.3.1.2.4. By Specimen
    • 6.3.2. Mexico Circulating Tumor Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Product
        • 6.3.2.2.4. By Specimen
    • 6.3.3. Canada Circulating Tumor Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Product
        • 6.3.3.2.4. By Specimen

7. Europe Circulating Tumor Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By Product
    • 7.2.4. By Specimen
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Circulating Tumor Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Product
        • 7.3.1.2.4. By Specimen
    • 7.3.2. Germany Circulating Tumor Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Product
        • 7.3.2.2.4. By Specimen
    • 7.3.3. United Kingdom Circulating Tumor Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Product
        • 7.3.3.2.4. By Specimen
    • 7.3.4. Italy Circulating Tumor Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Product
        • 7.3.4.2.4. By Specimen
    • 7.3.5. Spain Circulating Tumor Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Product
        • 7.3.5.2.4. By Specimen

8. Asia-Pacific Circulating Tumor Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By Product
    • 8.2.4. By Specimen
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Circulating Tumor Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Product
        • 8.3.1.2.4. By Specimen
    • 8.3.2. India Circulating Tumor Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Product
        • 8.3.2.2.4. By Specimen
    • 8.3.3. South Korea Circulating Tumor Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Product
        • 8.3.3.2.4. By Specimen
    • 8.3.4. Japan Circulating Tumor Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Product
        • 8.3.4.2.4. By Specimen
    • 8.3.5. Australia Circulating Tumor Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Product
        • 8.3.5.2.4. By Specimen

9. South America Circulating Tumor Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By Product
    • 9.2.4. By Specimen
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Circulating Tumor Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Product
        • 9.3.1.2.4. By Specimen
    • 9.3.2. Argentina Circulating Tumor Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Product
        • 9.3.2.2.4. By Specimen
    • 9.3.3. Colombia Circulating Tumor Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Product
        • 9.3.3.2.4. By Specimen

10. Middle East and Africa Circulating Tumor Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By Product
    • 10.2.4. By Specimen
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Circulating Tumor Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Product
        • 10.3.1.2.4. By Specimen
    • 10.3.2. Saudi Arabia Circulating Tumor Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Product
        • 10.3.2.2.4. By Specimen
    • 10.3.3. UAE Circulating Tumor Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Product
        • 10.3.3.2.4. By Specimen

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Product & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Greiner Bio One International GmbH
    • 15.6.2. LineaRx, Inc. (Vitatex, Inc.)
    • 15.6.3. Bio-Techne Corporation
    • 15.6.4. Biolidics Limited
    • 15.6.5. Fluxion Biosciences, Inc.
    • 15.6.6. Creatv MicroTech, Inc.
    • 15.6.7. Canopus Bioscience Ltd.
    • 15.6.8. AVIVA Biosciences Corp
    • 15.6.9. Miltenyi Biotec Inc
    • 15.6.10. QIAGEN NV

16. Strategic Recommendations